Health Catalyst Inc (HCAT) Stock Forecast & Price Target
Health Catalyst Inc · NASDAQ
$2.15+0.07 (+3.61%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Health Catalyst Inc, 2 rate it Buy or better, 8 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets range widely, $1.75 to $4.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $2.69 sits 25% above the current $2.15. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.00 next quarter toward $0.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Hold
Strong Buy00%
Buy220%
Hold880%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Health Catalyst Inc.
As of Jul, 2 of 10 firms rate HCAT a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HCAT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.00
Range $-0.03 – $0.07 · 5 analysts · -101% YoY
Next period, 5 analysts expect Health Catalyst Inc to earn $-0.00 a share (range $-0.03 – $0.07), versus $0.06 a year earlier. Full-year consensus is $0.04, growing to $0.09 the year after.
REVENUE · NEXT QUARTER
$62.9M
Range $62.4M – $64.0M · 5 analysts · -18% YoY
Revenue is expected to reach $62.9M (range $62.4M – $64.0M), -17.6% year-over-year. Full-year consensus is $266.9M, rising to $250.3M next year.
Top analysts covering Health Catalyst Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HCAT.
#1
Scott Schoenhaus
Keybanc · Rank #345
Buy
$4.00+85.6% to target
Overall win rate
29%
+ Follow
#2
Daniel Grosslight
Citigroup
Hold
$1.75-18.8% to target
Coverage
—
+ Follow
#3
Stan Berenshteyn
Wells Fargo
Hold
$1.75-18.8% to target
Coverage
—
+ Follow
#4
David Grossman
Stifel
Hold
$2.00-7.2% to target
Coverage
—
+ Follow
#5
Richard Close
Canaccord Genuity
Buy
$3.00+39.2% to target
Coverage
—
+ Follow
HCAT stock forecast FAQ
What is HCAT's average 12-month price target?+
The 9 analysts with a live target average $2.69 for Health Catalyst Inc over the next 12 months, ranging from a $4.00 high to a $1.75 low.
Is HCAT stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 10 analyst ratings, 2 are Buy or Strong Buy, 8 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HCAT?+
The Street-high target is $4.00 (Keybanc), and the Street-low is $1.75 (Wells Fargo). The average of all 9 active targets is $2.69.
How many Wall Street analysts cover HCAT?+
10 analysts have an active rating on Health Catalyst Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering HCAT?+
Among analysts who currently cover HCAT, Scott Schoenhaus of Keybanc has the strongest overall Quantellect track record (Rank #345). Their current call is Buy with a $4.00 target.
What is Health Catalyst Inc's projected EPS for next quarter?+
The consensus estimate is $-0.00 per share (range $-0.03 – $0.07) across 5 analysts. Full-year EPS is projected at $0.04, rising to $0.09 the following year.
How much revenue is Health Catalyst Inc expected to report next quarter?+
Consensus revenue is $62.9M (range $62.4M – $64.0M). Full-year revenue is projected at $266.9M, growing to $250.3M next year.
Have analysts been upgrading or downgrading HCAT lately?+
As of Jul, 2 of 10 firms rate HCAT a Buy (8 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HCAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
